实时全球研报
Novo Nordisk A/S (NOVOb.CO): Here Wegovy again! (week 10)...Wegovy Pill TRx tracker. New TRx high despite strong rebound last week
研报英文原文证据摘录
Novo Nordisk A/S (NOVOb.CO): Here Wegovy again! (week 10)...Wegovy Pill TRx tracker. New TRx high despite strong rebound last week
Novo Nordisk A/S (NOVOb.CO)
19 June 2026 Citi Research
Maintain Neutral – We maintain our Neutral/High Risk rating. Although our 26E sales estimates are at the upper end of Novo
guidance, we think 27E will remain a difficult year with further sales/EPS declines and continue to see significant long-term
pricing/competitive uncertainty in Novo’s core obesity market.
Figure 1. Wegovy pill launch trajectory Figure 2. Wegovy franchise
© 2026 Citigroup Inc. No redistribution without Citigroup’s written permission. © 2026 Citigroup Inc. No redistribution without Citigroup’s written permission.
The above material includes information based on market research The above material includes information based on market research
information obtained under license from the following information information obtained under license from the following information
services: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Oct services: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Jan
2019-Jun 2026, Copyright IQVIA, All Rights Reserved. 2026-Jun 2026, Copyright IQVIA, All Rights Reserved.
Source: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Oct 2019- Source: IQVIA Rapid Weekly, IQVIA National Prescription Audit™, Jan 2026-
Jun 2026, Copyright IQVIA, All Rights Reserved., Citi Research Jun 2026, Copyright IQVIA, All Rights Reserved., Citi Research
Figure 3. Wegovy pill TRx by dose Figure 4. Wegovy pill TRx by dose as % total Wegovy pill
© 2026 Citigroup Inc. No redistribution without Citigroup’s written permission.
The above material includes information based on market research © 2026 Citigroup Inc.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文，不做批量翻译；登录后在阅读器切换中文时才按需翻译。
打开研报阅读器